Managed Care Co Payments

Please use these coupon codes at any retail pharmacy for out of pocket copay assistance: BIN# 600428 GROUP# 06780131 PCN# 0678000 ID# 19062468510.

Indications and Usage

Cetraxal is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus.

Dosage and Administration

Contents of one single use container should be instilled into the affected ear twice daily (approximately 12 hours apart) for 7 days.

Dosage Forms and Strengths

Cetraxal is a sterile, preservative-free otic solution of ciprofloxacin hydrochloride equivalent to 0.2 % ciprofloxacin (0.5 mg in 0.25 mL) in each single use container.


History of hypersensitivity to ciprofloxacin.

Warnings and Precautions

Cetraxal is for otic use only.

Hypersensitivity: discontinue at the first appearance of a skin rash or any other sign of hypersensitivity.

Use of Cetraxal may result in overgrowth of nonsusceptible organisms.

Adverse Reactions

The most common adverse reactions reported in 2-3% of patients treated with Cetraxal were application site pain, ear pruritis, fungal ear superinfection, and headache.

Directions for Use

Patients should be advised that Cetraxal is for otic use only. It is not for ophthalmic or inhalation use. It is not for injection.

Cetraxal should be given 2 times each day (about 12 hours apart) in each infected ear.

Cetraxal should be used for as long as it is prescribed, even if the symptoms improve. The patient should be advised to follow these directions while on Cetraxal:

Wash their hands before use.

No need to warm the container like other otic antibiotics.  Twist off and discard top of container.

Lie with the affected ear upward and then instill the contents of one container into the ear. Maintain this position for at least one minute to facilitate penetration of the drops into the ear.

Repeat, if necessary, for the opposite ear.

Discard used container.

Store unused containers in pouch to protect from light.


Patients should be advised to immediately discontinue Cetraxal at the first appearance of a skin rash or any other sign of hypersensitivity.